Exact Mass: 315.1947

Exact Mass Matches: 315.1947

Found 500 metabolites which its exact mass value is equals to given mass value 315.1947, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Oxycodone

(1S,5R,13R,17S)-17-hydroxy-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one

C18H21NO4 (315.1471)


Oxycodone is only found in individuals that have used or taken this drug. It is a semisynthetic derivative of codeine that acts as a narcotic analgesic more potent and addicting than codeine. [PubChem]Oxycodone acts as a weak agonist at mu, kappa, and delta opioid receptors within the central nervous system (CNS). Oxycodone primarily affects mu-type opioid receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as oxycodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (kappa-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (mu and delta receptor agonist). This results in hyperpolarization and reduced neuronal excitability. D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AA - Natural opium alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics

   

Decanoylcarnitine (C10)

(3R)-3-(decanoyloxy)-4-(trimethylazaniumyl)butanoate

C17H33NO4 (315.2409)


Decanoylcarnitine is a member of the class of compounds known as acylcarnitines. More specifically, it is a decanoic acid ester of carnitine. Acylcarnitines were first discovered in the 1940s (PMID: 13825279 ). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Decanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine decanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494 ). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular decanoylcarnitine is elevated in the blood or plasma of individuals with obesity in adolescence (PMID: 26910390 ). It is also decreased in the blood or plasma of individuals with adolescent idiopathic scoliosis (PMID: 26928931 ). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279 ). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. Acylcarnitine useful in the diagnosis of fatty acid oxidation disorders and differentiation between biochemical phenotypes of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency deficiencyoxidation disorders.(PMID: 12385891) [HMDB]

   

(S)-3-Hydroxy-N-methylcoclaurine

4-{[(1S)-7-hydroxy-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}benzene-1,2-diol

C18H21NO4 (315.1471)


(S)-3-Hydroxy-N-methylcoclaurine is an intermediate in the biosynthesis of alkaloids (KEGG ID C05202). It is the 10th to last step in the synthesis of morphine and is converted from (s)-N-methylcoclaurine via the enzyme tyrosinase [EC:1.14.18.1]. It is then converted to (S)-reticuline. [HMDB] (S)-3-Hydroxy-N-methylcoclaurine is an intermediate in the biosynthesis of alkaloids (KEGG ID C05202). It is the 10th to last step in the synthesis of morphine and is converted from (s)-N-methylcoclaurine via the enzyme tyrosinase [EC:1.14.18.1]. It is then converted to (S)-reticuline.

   

Nororientaline

Nororientaline

C18H21NO4 (315.1471)


An isoquinoline alkaloid consisting of a tetrahydroisoquinoline core with 4-hydroxy-3-methoxybenzyl, methoxy and hydroxy substituents at positions 1, 6 and 7 respectively; major species at pH 7.3.

   

Norreticuline

(R)-Norreticuline

C18H21NO4 (315.1471)


   

Belladine

Belladine

C19H25NO3 (315.1834)


A phenethylamine alkaloid that is N-methyl-4-methoxyphenylethylamine carrying an additional N-(3,4-dimethoxybenzyl) substituent.

   

Cephalotaxine

Cephalotaxine

C18H21NO4 (315.1471)


Cephalotaxlen ((-)-Cephalotaxine) is an alkaloid that can be isolated from Cephalotaxus fortunei, with antileukemic and antiviral activities. Cephalotaxlen has anti-ZIKV (Zika virus) activity[1][2][3]. Cephalotaxlen ((-)-Cephalotaxine) is an alkaloid that can be isolated from Cephalotaxus fortunei, with antileukemic and antiviral activities. Cephalotaxlen has anti-ZIKV (Zika virus) activity[1][2][3].

   

Bremazocine

Bremazocine

C20H29NO2 (315.2198)


D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics

   

Butoctamide

Butoctamide hydrogen succinate

C16H29NO5 (315.2046)


Same as: D01498

   

2-Nitroestrone

3-Hydroxy-2-nitroestra-1,3,5(10)-trien-17-one

C18H21NO4 (315.1471)


   

4-Nitroestrone

3-Hydroxy-4-nitroestra-1,3,5(10)-trien-17-one

C18H21NO4 (315.1471)


   

Alizapride

6-methoxy-N-{[1-(prop-2-en-1-yl)pyrrolidin-2-yl]methyl}-2H-1,2,3-benzotriazole-5-carboxamide

C16H21N5O2 (315.1695)


D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents

   

(S)-Norreticuline

(S)-Norreticuline

C18H21NO4 (315.1471)


   

(S)-Nororientaline

(S)-Nororientaline

C18H21NO4 (315.1471)


   

Codeine N-oxide

14-hydroxy-10-methoxy-4-methyl-12-oxa-4λ⁵-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10,15-tetraen-4-one

C18H21NO4 (315.1471)


Codeine N-oxide is found in opium poppy. Codeine N-oxide is an alkaloid from Papaver somniferum (opium poppy). Alkaloid from Papaver somniferum (opium poppy). Codeine N-oxide is found in opium poppy.

   

(E)-Piperolein A

(6E)-7-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hept-6-en-1-one

C19H25NO3 (315.1834)


(e)-piperolein a is a member of the class of compounds known as benzodioxoles. Benzodioxoles are organic compounds containing a benzene ring fused to either isomers of dioxole. Dioxole is a five-membered unsaturated ring of two oxygen atoms and three carbon atoms (e)-piperolein a is practically insoluble (in water) and an extremely weak basic (essentially neutral) compound (based on its pKa). (e)-piperolein a can be found in herbs and spices, which makes (e)-piperolein a a potential biomarker for the consumption of this food product. (E)-Piperolein A is found in herbs and spices. (E)-Piperolein A is a minor constituent of Piper nigrum (pepper

   

(±)-Pandamarine

3-methyl-6-{4-[(2E)-4-methyl-5-oxo-2,5-dihydro-1H-pyrrol-2-ylidene]butyl}-1,6-diazaspiro[4.5]dec-3-en-2-one

C18H25N3O2 (315.1947)


(±)-Pandamarine is a major alkaloid from leaves of Pandanus amaryllifolius. Major alkaloid from leaves of Pandanus amaryllifolius

   

N-Dihydroferuloyltyramine

3-(4-Hydroxy-3-methoxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]propanimidate

C18H21NO4 (315.1471)


N-Dihydroferuloyltyramine is found in fruits. N-Dihydroferuloyltyramine is an alkaloid from stems of cherimoya (Annona cherimola). Alkaloid from stems of cherimoya (Annona cherimola). N-Dihydroferuloyltyramine is found in fruits.

   

Erythratine

19-methoxy-5,7-dioxa-13-azapentacyclo[11.7.0.0¹,¹⁶.0²,¹⁰.0⁴,⁸]icosa-2,4(8),9,16-tetraen-18-ol

C18H21NO4 (315.1471)


Erythratine is found in green vegetables. Erythratine is an alkaloid from the seeds of Erythrina glauca (gallito

   

Val-Val-Val

2-({2-[(2-amino-1-hydroxy-3-methylbutylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-3-methylbutanoate

C15H29N3O4 (315.2158)


Val-val-val is classified as a member of the oligopeptides. Oligopeptides are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds. Val-val-val is considered to be a slightly soluble (in water) and a weak acidic compound. Val-val-val can be found in feces.

   

Mitiglinide

Calcium 2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate

C19H25NO3 (315.1834)


Mitiglinide is only found in individuals that have used or taken this drug. It is a drug for the treatment of type 2 diabetes.Mitiglinide is thought to stimulate insulin secretion by binding to and blocking ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. Closure of potassium channels causes depolarization which stimulates calcium influx through voltage-gated calcium channels. High intracellular calcium subsequently triggers the exocytosis of insulin granules.

   

Alizapride

6-methoxy-N-{[1-(prop-2-en-1-yl)pyrrolidin-2-yl]methyl}-2H-1,2,3-benzotriazole-5-carboxamide

C16H21N5O2 (315.1695)


Alizapride is only found in individuals that have used or taken this drug. It is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting.The anti-emetic action of Alizapride is due to its antagonist activity at D2 receptors in the chemoreceptor trigger zone (CTZ) in the central nervous system (CNS)—this action prevents nausea and vomiting triggered by most stimuli. Structurally similar to metoclopramide and, therefore, shares similar other atributres related to emesis and prokinetics. D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents

   

Rotigotine

6-{propyl[2-(thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol

C19H25NOS (315.1657)


Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinsons disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours. Like other dopamine agonists, rotigotine has been shown to possess antidepressant effects and may be useful in the treatment of depression as well. Rotigotine was developed by Aderis Pharmaceuticals. In 1998, Aderis licensed worldwide development and commercialization rights for rotigotine to the German pharmaceutical company Schwarz Pharma (today a subsidiary of the Belgian company UCB S.A.). The drug has been approved by the EMEA for use in Europe in 2006 and is today being sold in several European countries. In 2007, the Neupro patch was approved by the Food and Drug Administration (FDA) as the first transdermal treatment of Parkinsons disease in the United States. However, as of 2008, Schwarz Pharma has recalled all Neupro patches in the United States and some in Europe because of problems with the delivery mechanism. Rotigotine has been authorized as a treatment for RLS since August 2008. D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists

   

Saxagliptin

(1S,3S,5S)-2-((2S)-Amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl)-2-azabicyclo(3.1.0)hexane-3-carbonitrile

C18H25N3O2 (315.1947)


Saxagliptin (rINN), previously identified as BMS-477118, is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. It was developed by Bristol-Myers Squibb. A New Drug Application for saxagliptin in the treatment of type 2 diabetes was submitted to the FDA in June 2008. It was based on a drug development program with 8 randomized trials: 1 phase 2 dose-ranging (2.5 - 100 mg/d) study; 6 phase 3, 24-week controlled trials with additional controlled follow-up from 12 to 42 months, double-blinded throughout; and one 12-week mechanism-of-action trial with a 2-year follow-up period. In June 2008, it was announced that Onglyza would be the trade name under which saxagliptin will be marketed. A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D054795 - Incretins D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor

   

6-Methylnonanoylcarnitine

3-[(6-methylnonanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H33NO4 (315.2409)


6-Methylnonanoylcarnitine is an acylcarnitine. More specifically, it is an 6-methylnonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Methylnonanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-Methylnonanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Methylnonanoylcarnitine

3-[(5-methylnonanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H33NO4 (315.2409)


5-Methylnonanoylcarnitine is an acylcarnitine. More specifically, it is an 5-methylnonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Methylnonanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Methylnonanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

8-Methylnonanoylcarnitine

3-[(8-methylnonanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H33NO4 (315.2409)


8-Methylnonanoylcarnitine is an acylcarnitine. More specifically, it is an 8-methylnonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-Methylnonanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 8-Methylnonanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-Methylnonanoylcarnitine

3-[(7-methylnonanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H33NO4 (315.2409)


7-Methylnonanoylcarnitine is an acylcarnitine. More specifically, it is an 7-methylnonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Methylnonanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 7-Methylnonanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Methylnonanoylcarnitine

3-[(4-methylnonanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H33NO4 (315.2409)


4-Methylnonanoylcarnitine is an acylcarnitine. More specifically, it is an 4-methylnonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Methylnonanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Methylnonanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Methylnonanoylcarnitine

3-[(3-methylnonanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H33NO4 (315.2409)


3-Methylnonanoylcarnitine is an acylcarnitine. More specifically, it is an 3-methylnonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Methylnonanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Methylnonanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(6Z)-Oct-6-enedioylcarnitine

3-[(7-carboxyhept-6-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H25NO6 (315.1682)


(6Z)-oct-6-enedioylcarnitine is an acylcarnitine. More specifically, it is an (6Z)-oct-6-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6Z)-oct-6-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (6Z)-oct-6-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Oct-4-enedioylcarnitine

3-[(7-carboxyhept-4-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H25NO6 (315.1682)


oct-4-enedioylcarnitine is an acylcarnitine. More specifically, it is an oct-4-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. oct-4-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine oct-4-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Oct-5-enedioylcarnitine

3-[(7-carboxyhept-5-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H25NO6 (315.1682)


oct-5-enedioylcarnitine is an acylcarnitine. More specifically, it is an oct-5-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. oct-5-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine oct-5-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2E)-Oct-2-enedioylcarnitine

3-[(7-carboxyhept-2-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H25NO6 (315.1682)


(2E)-oct-2-enedioylcarnitine is an acylcarnitine. More specifically, it is an (2E)-oct-2-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E)-oct-2-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E)-oct-2-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2Z)-6-Hydroxynon-2-enoylcarnitine

3-[(6-Hydroxynon-2-enoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C16H29NO5 (315.2046)


(2Z)-6-hydroxynon-2-enoylcarnitine is an acylcarnitine. More specifically, it is an (2Z)-6-hydroxynon-2-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2Z)-6-hydroxynon-2-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2Z)-6-hydroxynon-2-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Hydroxynon-7-enoylcarnitine

3-[(6-hydroxynon-7-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H29NO5 (315.2046)


6-hydroxynon-7-enoylcarnitine is an acylcarnitine. More specifically, it is an 6-hydroxynon-7-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-hydroxynon-7-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-hydroxynon-7-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Hydroxynon-3-enoylcarnitine

3-[(6-Hydroxynon-3-enoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C16H29NO5 (315.2046)


6-hydroxynon-3-enoylcarnitine is an acylcarnitine. More specifically, it is an 6-hydroxynon-3-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-hydroxynon-3-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-hydroxynon-3-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Hydroxynon-4-enoylcarnitine

3-[(6-hydroxynon-4-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H29NO5 (315.2046)


6-hydroxynon-4-enoylcarnitine is an acylcarnitine. More specifically, it is an 6-hydroxynon-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-hydroxynon-4-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-hydroxynon-4-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Hydroxynon-5-enoylcarnitine

3-[(6-hydroxynon-5-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H29NO5 (315.2046)


6-hydroxynon-5-enoylcarnitine is an acylcarnitine. More specifically, it is an 6-hydroxynon-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-hydroxynon-5-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-hydroxynon-5-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Hydroxynon-6-enoylcarnitine

3-[(6-hydroxynon-6-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H29NO5 (315.2046)


6-hydroxynon-6-enoylcarnitine is an acylcarnitine. More specifically, it is an 6-hydroxynon-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-hydroxynon-6-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-hydroxynon-6-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-Oxononanoylcarnitine

3-[(7-oxononanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H29NO5 (315.2046)


7-Oxononanoylcarnitine is an acylcarnitine. More specifically, it is an 7-oxononanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Oxononanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 7-Oxononanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Oxononanoylcarnitine

3-[(5-Oxononanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C16H29NO5 (315.2046)


5-Oxononanoylcarnitine is an acylcarnitine. More specifically, it is an 5-oxononanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Oxononanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Oxononanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

8-Oxononanoylcarnitine

3-[(8-oxononanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H29NO5 (315.2046)


8-Oxononanoylcarnitine is an acylcarnitine. More specifically, it is an 8-oxononanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-Oxononanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 8-Oxononanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Oxononanoylcarnitine

3-[(3-Oxononanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C16H29NO5 (315.2046)


3-Oxononanoylcarnitine is an acylcarnitine. More specifically, it is an 3-oxononanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Oxononanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Oxononanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Oxononanoylcarnitine

3-[(6-Oxononanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C16H29NO5 (315.2046)


6-Oxononanoylcarnitine is an acylcarnitine. More specifically, it is an 6-oxononanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Oxononanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-Oxononanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Oxononanoylcarnitine

3-[(4-oxononanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H29NO5 (315.2046)


4-Oxononanoylcarnitine is an acylcarnitine. More specifically, it is an 4-oxononanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Oxononanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Oxononanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

9-Oxononanoylcarnitine

3-[(9-oxononanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H29NO5 (315.2046)


9-Oxononanoylcarnitine is an acylcarnitine. More specifically, it is an 9-oxononanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-Oxononanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 9-Oxononanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Lauroyl Aspartic acid

2-(Dodecanoylamino)butanedioic acid

C16H29NO5 (315.2046)


N-lauroyl aspartic acid, also known as N-lauroyl aspartate belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Lauric acid amide of Aspartic acid. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Lauroyl Aspartic acid is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Lauroyl Aspartic acid is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Myristoyl Serine

3-hydroxy-2-tetradecanamidopropanoic acid

C17H33NO4 (315.2409)


N-myristoyl serine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Myristic acid amide of Serine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Myristoyl Serine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Myristoyl Serine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

(-)-Bremazocine

1-ethyl-10-[(1-hydroxycyclopropyl)methyl]-13,13-dimethyl-10-azatricyclo[7.3.1.0^{2,7}]trideca-2(7),3,5-trien-4-ol

C20H29NO2 (315.2198)


   

(2R,3R,6S)-4-Methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-ol

(2R,3R,6S)-4-Methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-ol

C18H21NO4 (315.1471)


   

Dihydroethidium

5-ethyl-6-phenyl-5,6-dihydrophenanthridine-3,8-diamine

C21H21N3 (315.1735)


   

Fendiline

Celltech brand OF fendiline hydrochloride

C23H25N (315.1987)


C - Cardiovascular system > C08 - Calcium channel blockers > C08E - Non-selective calcium channel blockers > C08EA - Phenylalkylamine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

   

Indicine-N-oxide

7-({[2,3-dihydroxy-2-(propan-2-yl)butanoyl]oxy}methyl)-1-hydroxy-1,2,3,4,5,7a-hexahydropyrrolizin-4-ium-4-olate

C15H25NO6 (315.1682)


   

Pamaquine

8-((4-(Diethylamino)-1-methylbutyl)amino)-6-methoxyquinoline

C19H29N3O (315.2311)


   

(R)-N1-((S)-3,3-Dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide

2-[(Dihydroxycarbonimidoyl)methyl]-N-[2,2-dimethyl-1-(methyl-C-hydroxycarbonimidoyl)propyl]-4-methylpentanimidate

C15H29N3O4 (315.2158)


   

gibberellin A12-aldehyde

(1R,2S,3S,4R,8S,9S,12R)-2-formyl-4,8-dimethyl-13-methylidenetetracyclo[10.2.1.0¹,⁹.0³,⁸]pentadecane-4-carboxylate

C20H27O3 (315.196)


Gibberellin a12-aldehyde is a member of the class of compounds known as c20-gibberellins. C20-gibberellins are gibberellins with carboxy groups in positions 7 and 18 and some also in 20, while others have an aldehyde group in the latter position. Gibberellin a12-aldehyde is practically insoluble (in water) and a weakly acidic compound (based on its pKa). Gibberellin a12-aldehyde can be found in a number of food items such as custard apple, yellow bell pepper, giant butterbur, and java plum, which makes gibberellin a12-aldehyde a potential biomarker for the consumption of these food products.

   

Synribo

(1S-(1.ALPHA.,3AS*,14B.BETA.))-1,5,6,8,9,14B-HEXAHYDRO-2-METHOXY-4H-CYCLOPENTA(A)(1,3)DIOXOLO(4,5-H)PYRROLO(2,1-B)(3)BENZAZEPIN-1-OL

C18H21NO4 (315.1471)


Cephalotaxine is a benzazepine alkaloid isolated from Cephalotaxus harringtonia. It is a benzazepine alkaloid, a benzazepine alkaloid fundamental parent, an organic heteropentacyclic compound, an enol ether, a cyclic acetal, a secondary alcohol and a tertiary amino compound. Omacetaxine is a semisynthetic cephataxine that acts as a protein translation inhibitor and is used to treated chronic myeloid leukemia that is resistant to tyrosine kinase receptor antagonists. Omacetaxine is associated with a low rate of serum enzyme elevation during therapy, but has not been linked to cases of clinically apparent liver injury with jaundice. Cephalotaxine is a natural product found in Cephalotaxus hainanensis, Cephalotaxus harringtonia, and other organisms with data available. Omacetaxine is a protein translation inhibitor and cytotoxic plant alkaloid homoharringtonine isolated from the evergreen tree Cephalotaxus, with potential antineoplastic activity. Although the exact mechanism of action has not been fully elucidated, upon administration, omacetaxine targets and binds to the 80S ribosome in eukaryotic cells and inhibits protein synthesis by interfering with chain elongation. This reduces levels of certain oncoproteins and anti-apoptotic proteins. Semisynthetic derivative of harringtonine that acts as a protein synthesis inhibitor and induces APOPTOSIS in tumor cells. It is used in the treatment of MYELOID LEUKEMIA, CHRONIC. See also: Omacetaxine Mepesuccinate (active moiety of). D000970 - Antineoplastic Agents > D000972 - Antineoplastic Agents, Phytogenic > D006248 - Harringtonines C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors C274 - Antineoplastic Agent > C1931 - Antineoplastic Plant Product A benzazepine alkaloid isolated from Cephalotaxus harringtonia. C1907 - Drug, Natural Product Cephalotaxlen ((-)-Cephalotaxine) is an alkaloid that can be isolated from Cephalotaxus fortunei, with antileukemic and antiviral activities. Cephalotaxlen has anti-ZIKV (Zika virus) activity[1][2][3]. Cephalotaxlen ((-)-Cephalotaxine) is an alkaloid that can be isolated from Cephalotaxus fortunei, with antileukemic and antiviral activities. Cephalotaxlen has anti-ZIKV (Zika virus) activity[1][2][3].

   

Indicine N-oxide

Indicine N-oxide

C15H25NO6 (315.1682)


   
   
   
   

(E)-(4-Hydroxycinnamoyl)-epilupinine

(E)-(4-Hydroxycinnamoyl)-epilupinine

C19H25NO3 (315.1834)


   

Bisdehydroneostemonine

Bisdehydroneostemonine

C18H21NO4 (315.1471)


   
   

(+)-11alpha-Hydroxyerythravine

(+)-11alpha-Hydroxyerythravine

C18H21NO4 (315.1471)


   

1-O-Acetylnorpluviine

1-O-Acetyl-9-O-demethylpluviine

C18H21NO4 (315.1471)


   

Stephaoxocanine

Stephaoxocanine

C18H21NO4 (315.1471)


   

O-Methyloduline

O-Methyloduline

C18H21NO4 (315.1471)


   
   

O-methylbalsamide

(+)-O-methylbalsamide

C18H21NO4 (315.1471)


   

9,10-Dimethoxy-1-methyllycorenan-7-one #

9,10-Dimethoxy-1-methyllycorenan-7-one #

C18H21NO4 (315.1471)


   
   

1-Carboxytrypargine

1-Carboxytrypargine

C16H21N5O2 (315.1695)


   

Dihydroperfamine

Dihydroperfamine

C18H21NO4 (315.1471)


   
   

(-)-Stepharinosine

(-)-Stepharinosine

C18H21NO4 (315.1471)


   

Haiderine

O-Demethylhirsutine

C18H21NO4 (315.1471)


   
   

Isocephalotaxine

Isocephalotaxine

C18H21NO4 (315.1471)


   

(+)-Dihydroperfamine

(+)-Dihydroperfamine

C18H21NO4 (315.1471)


   

(S)-3-Hydroxy-N-methylcoclaurine

(S)-3-Hydroxy-N-methylcoclaurine

C18H21NO4 (315.1471)


An isoquinoline alkaloid having a tetrahydroisoquinoline core with 3,4-dihydroxybenzyl, methoxy and hydroxy groups at the 1-, 6- and 7-positions respectively; major species at pH 7.3.

   

3-Hydroxy-7-O-methylcoclaurine

3-Hydroxy-7-O-methylcoclaurine

C18H21NO4 (315.1471)


   

6-O-Methyllaudanosoline

6-O-Methyllaudanosoline

C18H21NO4 (315.1471)


   

(Z)-(4-Hydroxycinnamoyl)-epilupinine

(Z)-(4-Hydroxycinnamoyl)-epilupinine

C19H25NO3 (315.1834)


   

Lupinyl trans-p-coumarate

(-)-(trans-4-Hydroxycinnamoyl)lupinine

C19H25NO3 (315.1834)


   
   

1-(3,4-Dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)propan-2-amine

1-(3,4-Dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)propan-2-amine

C19H25NO3 (315.1834)


   
   

3,4,5-trimethoxy-N-(1-phenylethyl)benzamide

3,4,5-trimethoxy-N-(1-phenylethyl)benzamide

C18H21NO4 (315.1471)


   

1-benzhydryl-3-phenoxyazetidine

1-benzhydryl-3-phenoxyazetidine

C22H21NO (315.1623)


   

17β-Hydroxy-androstano[3,2-c]isoxazole

17β-Hydroxy-androstano[3,2-c]isoxazole

C20H29NO2 (315.2198)


   

CHEMBL355194

CHEMBL355194

C20H19N4+ (315.161)


   

N-(4-Hydroxyphenethyl)-2,4-dodecadienamid

N-(4-Hydroxyphenethyl)-2,4-dodecadienamid

C20H29NO2 (315.2198)


   

5-[(E)-3-hydroxybut-1-enyl]-4-[4-[(E)-3-oxobut-1-enyl]anilino]oxolan-2-one

5-[(E)-3-hydroxybut-1-enyl]-4-[4-[(E)-3-oxobut-1-enyl]anilino]oxolan-2-one

C18H21NO4 (315.1471)


   

SCHEMBL1478023

SCHEMBL1478023

C19H25NO3 (315.1834)


   

Alkaloid GB13

Alkaloid GB13

C20H29NO2 (315.2198)


   

Me ether- Dihydroerysodine

Me ether- Dihydroerysodine

C19H25NO3 (315.1834)


   
   

8,14-Dihydro-norsalutaridin

8,14-Dihydro-norsalutaridin

C18H21NO4 (315.1471)


   
   

17-demethylsinomenine|N-demethyl-sinomenine|N-demethylsinomenine

17-demethylsinomenine|N-demethyl-sinomenine|N-demethylsinomenine

C18H21NO4 (315.1471)


   

(E,E)-N-(4-Hydroxyphenethyl)-2,4-dodecadienamide

(E,E)-N-(4-Hydroxyphenethyl)-2,4-dodecadienamide

C20H29NO2 (315.2198)


   
   

4-(3-methoxy-4-hydroxyphenyl)-4-<2-(acetylmethylamino)ethyl>cyclohexadienone

4-(3-methoxy-4-hydroxyphenyl)-4-<2-(acetylmethylamino)ethyl>cyclohexadienone

C18H21NO4 (315.1471)


   

(7Z,10S,12Z,13aS)-7,13-epoxy-2,3,9,10,11,13a-hexahydro-5,6-dimethoxy-1H-cyclodec[ij]isoquinolin-10-ol|stephalonganine A

(7Z,10S,12Z,13aS)-7,13-epoxy-2,3,9,10,11,13a-hexahydro-5,6-dimethoxy-1H-cyclodec[ij]isoquinolin-10-ol|stephalonganine A

C18H21NO4 (315.1471)


   

(-)-(trans-4-Hydroxycinnamoyl)lupinine

(-)-(trans-4-Hydroxycinnamoyl)lupinine

C19H25NO3 (315.1834)


   

2-O-acetylchlidanthine

2-O-acetylchlidanthine

C18H21NO4 (315.1471)


   
   

4-[2-(Acetylmethylamino)ethyl]-4-(4-hydroxy-3-methoxyphenyl)-2,4-cyclohexadien-1-one

4-[2-(Acetylmethylamino)ethyl]-4-(4-hydroxy-3-methoxyphenyl)-2,4-cyclohexadien-1-one

C18H21NO4 (315.1471)


   

trans-3-isobutyl-4-[4-(3-methyl-3-butenyloxy)phenyl]pyrrolidine-2,5-dione

trans-3-isobutyl-4-[4-(3-methyl-3-butenyloxy)phenyl]pyrrolidine-2,5-dione

C19H25NO3 (315.1834)


   

1-Methoxy-2-hydroxy-schelhammericine

1-Methoxy-2-hydroxy-schelhammericine

C19H25NO3 (315.1834)


   

2,3-dihydroxy-2-(1-hydroxyethyl)-3-methylbutanoic acid (2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl)methyl ester|leptanthine

2,3-dihydroxy-2-(1-hydroxyethyl)-3-methylbutanoic acid (2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl)methyl ester|leptanthine

C15H25NO6 (315.1682)


   
   

11beta-hydroxyerysodine

11beta-hydroxyerysodine

C18H21NO4 (315.1471)


   

10-Epimartensine A|Martensine A

10-Epimartensine A|Martensine A

C18H25N3O2 (315.1947)


   

(14E)-solanapyrone O

(14E)-solanapyrone O

C19H25NO3 (315.1834)


   
   

solanapyrone L

solanapyrone L

C19H25NO3 (315.1834)


   

N-de(phenylethyl)isohericerin

N-de(phenylethyl)isohericerin

C19H25NO3 (315.1834)


   
   
   

(R)-3-(2-hydroxy-3-methoxy-3-methylbutyl)-5-(3-methyl-1-oxo-2-butenyl)indole

(R)-3-(2-hydroxy-3-methoxy-3-methylbutyl)-5-(3-methyl-1-oxo-2-butenyl)indole

C19H25NO3 (315.1834)


   

11-O-methylcrinamine

11-O-methylcrinamine

C18H21NO4 (315.1471)


   
   

Morphinan-6,14-diol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5.alpha.,6.alpha.)-

Morphinan-6,14-diol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5.alpha.,6.alpha.)-

C18H21NO4 (315.1471)


   
   

SCHEMBL17713946

SCHEMBL17713946

C18H21NO4 (315.1471)


   

1-[(2E)-1-oxo-7-(3,4-methylenedioxy)phenylheptenyl]piperidine|piperine S

1-[(2E)-1-oxo-7-(3,4-methylenedioxy)phenylheptenyl]piperidine|piperine S

C19H25NO3 (315.1834)


   

Isocryprochine|isocryprocine

Isocryprochine|isocryprocine

C19H25NO3 (315.1834)


   

Isolucidinine

Isolucidinine

C19H25NO3 (315.1834)


   
   

inakt.Leucyl-glycyl-leucin-methylester|Leucyl=>glycyl=>leucin-methylester|leucyl=>glycyl=>leucine methyl ester

inakt.Leucyl-glycyl-leucin-methylester|Leucyl=>glycyl=>leucin-methylester|leucyl=>glycyl=>leucine methyl ester

C15H29N3O4 (315.2158)


   

(-)-indolactam I|(-)-indolactam-Ile|Indolactam I

(-)-indolactam I|(-)-indolactam-Ile|Indolactam I

C18H25N3O2 (315.1947)


   
   

4-methoxy-1-methyl-3-(2S-acetoxy-3-ene-butyl)-2-quinolone

4-methoxy-1-methyl-3-(2S-acetoxy-3-ene-butyl)-2-quinolone

C18H21NO4 (315.1471)


   

16-hydroxy-3beta,15-dimethoxy-erythrin-1(6)-en-2-one|Erysotinon|erysotinone

16-hydroxy-3beta,15-dimethoxy-erythrin-1(6)-en-2-one|Erysotinon|erysotinone

C18H21NO4 (315.1471)


   
   
   
   
   
   
   
   
   

fendiline

fendiline

C23H25N (315.1987)


C - Cardiovascular system > C08 - Calcium channel blockers > C08E - Non-selective calcium channel blockers > C08EA - Phenylalkylamine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

   
   
   
   
   
   
   
   
   
   
   
   
   

NCI60_000712

Butanoic acid,3-dihydroxy-2-(1-methylethyl)- (2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl) methyl ester, N-oxide, (1R-(1.alpha.,7(2R*,3S*),7a.beta))-

C15H25NO6 (315.1682)


Indicine N-oxide is a natural product found in Tournefortia argentea with data available. Indicine-N-Oxide is a natural pyrrolizidine alkaloid with antineoplastic properties. Indicine-N-oxide alkylates and crosslinks DNA. (NCI04)

   

Rinderine N-oxide

[(7S,8R)-7-hydroxy-4-oxido-5,6,7,8-tetrahydro-3H-pyrrolizin-4-ium-1-yl]methyl (2S)-2-hydroxy-2-[(1R)-1-hydroxyethyl]-3-methylbutanoate

C15H25NO6 (315.1682)


   

Echinatine oxide

Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)- (2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl) methyl ester, N-oxide, (1R-(1.alpha.,7(2R*,3S*),7a.b.eta.))-

C15H25NO6 (315.1682)


   

Lycopsamine N-oxide

Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, (2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl)methyl ester, N-oxide, [1R-[1?,7(2S*,3R*),7a?]]-; Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, (2,3,5,7a-tetrahydro-1-hydroxy-4-oxido-1H-pyrrolizin-7-yl)methyl ester, [1R-[1?,7(2S*,3R*),7a?]]-; Intermedine N-oxide

C15H25NO6 (315.1682)


Lycopsamine N-oxide is a natural product found in Symphytum officinale, Neatostema apulum, and Idea leuconoe with data available.

   

oxycodone

oxycodone

C18H21NO4 (315.1471)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AA - Natural opium alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics CONFIDENCE standard compound; INTERNAL_ID 1602 IPB_RECORD: 1423; CONFIDENCE confident structure

   

Safranin

Safranin

[C20H19N4]+ (315.161)


Acquisition and generation of the data is financially supported by the Max-Planck-Society IPB_RECORD: 2561; CONFIDENCE confident structure

   

Safranine

3,7-Diamino-2,8-dimethyl-5-phenylphenazin-5-ium

[C20H19N4]+ (315.161)


Acquisition and generation of the data is financially supported in part by CREST/JST.

   

Saxagliptin (BMS-477118,Onglyza)

"Saxagliptin (BMS-477118,Onglyza)"

C18H25N3O2 (315.1947)


   

2,3-Dimethoxy-15-methyl-4b,5,6,9,8a,10-hexahydro-16-oxa-8a-aza-cyclopenta[a]phenanthren-17-one

"NCGC00160299-01!2,3-Dimethoxy-15-methyl-4b,5,6,9,8a,10-hexahydro-16-oxa-8a-aza-cyclopenta[a]phenanthren-17-one"

C18H21NO4 (315.1471)


   

(2E,4E)-N-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienamide

NCGC00380344-01!(2E,4E)-N-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienamide

C20H29NO2 (315.2198)


   

Codeine N-Oxide

(3R,4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-3-oxido-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-ol

C18H21NO4 (315.1471)


   

C17H21N3O3_10b-Hydroxy-3-isobutyl-6,10b,11,11a-tetrahydro-2H-pyrazino[1,2:1,5]pyrrolo[2,3-b]indole-1,4(3H,5aH)-dione

NCGC00380254-01_C17H21N3O3_10b-Hydroxy-3-isobutyl-6,10b,11,11a-tetrahydro-2H-pyrazino[1,2:1,5]pyrrolo[2,3-b]indole-1,4(3H,5aH)-dione

C17H21N3O3 (315.1583)


   

Decanoylcarnitine

Decanoylcarnitine

C17H33NO4 (315.2409)


   

(2E,4E)-N-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienamide

(2E,4E)-N-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienamide

C20H29NO2 (315.2198)


   
   

Decanoyl-L-carnitine

Decanoyl-L-carnitine

C17H33NO4 (315.2409)


CONFIDENCE standard compound; INTERNAL_ID 249

   

N-methylcoclaurine N-oxide

N-methylcoclaurine N-oxide

[C18H21NO4]- (315.1471)


   

Intermedine N-oxide

Intermedine N-oxide

C15H25NO6 (315.1682)


CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2272

   

Lycopsamine N-oxide

Lycopsamine N-oxide

C15H25NO6 (315.1682)


CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2294

   

Nonyltyrazolone

Nonyltyrazolone

C19H25NO3 (315.1834)


   

(2E,4E)-N-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienamide [IIN-based on: CCMSLIB00000846683]

NCGC00380344-01!(2E,4E)-N-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienamide [IIN-based on: CCMSLIB00000846683]

C20H29NO2 (315.2198)


   

(2E,4E)-N-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienamide [IIN-based: Match]

NCGC00380344-01!(2E,4E)-N-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienamide [IIN-based: Match]

C20H29NO2 (315.2198)


   

Decanoyl-carnitine; AIF; CE0; CorrDec

Decanoyl-carnitine; AIF; CE0; CorrDec

C17H33NO4 (315.2409)


   

Decanoyl-carnitine; AIF; CE10; CorrDec

Decanoyl-carnitine; AIF; CE10; CorrDec

C17H33NO4 (315.2409)


   

Decanoyl-carnitine; AIF; CE30; CorrDec

Decanoyl-carnitine; AIF; CE30; CorrDec

C17H33NO4 (315.2409)


   

Decanoyl-carnitine; AIF; CE0; MS2Dec

Decanoyl-carnitine; AIF; CE0; MS2Dec

C17H33NO4 (315.2409)


   

Decanoyl-carnitine; AIF; CE10; MS2Dec

Decanoyl-carnitine; AIF; CE10; MS2Dec

C17H33NO4 (315.2409)


   

Decanoyl-carnitine; AIF; CE30; MS2Dec

Decanoyl-carnitine; AIF; CE30; MS2Dec

C17H33NO4 (315.2409)


   
   
   
   
   

Dehydroxyoxitropium

Dehydroxyoxitropium

C19H25NO3 (315.1834)


   
   
   
   

Pentazocine trans acid

Pentazocine trans acid

C19H25NO3 (315.1834)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

L-Hexanoylcarnitine n-butyl ester

L-Hexanoylcarnitine n-butyl ester

C17H33NO4 (315.2409)


   

3-O-Methyldobutamine

3-O-Methyldobutamine

C19H25NO3 (315.1834)


   

Mitiglinide

2-benzyl-4-(octahydro-1H-isoindol-2-yl)-4-oxobutanoic acid

C19H25NO3 (315.1834)


C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98079 - Meglitinide Antidiabetic Agent A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins D007004 - Hypoglycemic Agents

   

Rotigotine

6-{propyl[2-(thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol

C19H25NOS (315.1657)


N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents > N04BC - Dopamine agonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist Rotigotine is a potent dopamine receptor agonist with Ki values of 0.71?nM, 4-15?nM, and 83?nM for the dopamine D3 receptor and D2, D5, D4 receptors and dopamine D1 receptor. Rotigotine a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor. Rotigotine can be used for parkinson's disease (PD) research[1][2][3][4].

   

saxagliptin

(1S,3S,5S)-2-[(2S)-2-amino-2-[(1r,3R,5R,7S)-3-hydroxyadamantan-1-yl]acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile

C18H25N3O2 (315.1947)


A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D054795 - Incretins D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor

   

Erythratine

19-methoxy-5,7-dioxa-13-azapentacyclo[11.7.0.0^{1,16}.0^{2,10}.0^{4,8}]icosa-2,4(8),9,16-tetraen-18-ol

C18H21NO4 (315.1471)


   

(E)-Piperolein A

(6E)-7-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hept-6-en-1-one

C19H25NO3 (315.1834)


   

n-dihydroferuloyltyramine

3-(4-hydroxy-3-methoxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]propanamide

C18H21NO4 (315.1471)


   

Codeigene

14-hydroxy-10-methoxy-4-methyl-12-oxa-4$l^{5}-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10,15-tetraen-4-one

C18H21NO4 (315.1471)


   

(±)-Pandamarine

3-methyl-6-{4-[(2E)-4-methyl-5-oxo-2,5-dihydro-1H-pyrrol-2-ylidene]butyl}-1,6-diazaspiro[4.5]dec-3-en-2-one

C18H25N3O2 (315.1947)


   

(2E,4E)-N-[2-(4-Hydroxyphenyl)ethyl]-2,4-dodecadienamide

(2E,4E)-N-[2-(4-Hydroxyphenyl)ethyl]-2,4-dodecadienamide

C20H29NO2 (315.2198)


   

CAR 10:0

3-(decanoyloxy)-4-(trimethylazaniumyl)butanoate

C17H33NO4 (315.2409)


   

NA 20:6;O

Dodeca-2E,4E-dienoic acid 4-hydroxy-2-phenylethylamide

C20H29NO2 (315.2198)


   

1,3,5-Triazine,hexahydro-1,3,5-triphenyl-

1,3,5-Triazine,hexahydro-1,3,5-triphenyl-

C21H21N3 (315.1735)


   

1-BENZYL-2-(2-(1-METHYL-1H-PYRROL-2-YL)ETHYL)-1H-BENZO[D]IMIDAZOLE

1-BENZYL-2-(2-(1-METHYL-1H-PYRROL-2-YL)ETHYL)-1H-BENZO[D]IMIDAZOLE

C21H21N3 (315.1735)


   

2-ethylhexyl dihydrogen phosphate,2-(2-hydroxyethylamino)ethanol

2-ethylhexyl dihydrogen phosphate,2-(2-hydroxyethylamino)ethanol

C12H30NO6P (315.1811)


   

1-(3,3-diphenylpropyl)piperidinium chloride

1-(3,3-diphenylpropyl)piperidinium chloride

C20H26ClN (315.1754)


   

Dopamantine

Dopamantinum [INN-Latin]

C19H25NO3 (315.1834)


C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent

   

N-BOC-AMINO-(1,4-DIOXA-SPIRO[4.5]DEC-8-YL)-ACETICACID

N-BOC-AMINO-(1,4-DIOXA-SPIRO[4.5]DEC-8-YL)-ACETICACID

C15H25NO6 (315.1682)


   

DIETHYL 2-(1-(TERT-BUTOXYCARBONYL)AZETIDIN-3-YL)MALONATE

DIETHYL 2-(1-(TERT-BUTOXYCARBONYL)AZETIDIN-3-YL)MALONATE

C15H25NO6 (315.1682)


   

Boc-L-aspartic acid 4-cyclohexyl ester

Boc-L-aspartic acid 4-cyclohexyl ester

C15H25NO6 (315.1682)


   

diphenyl-[(3S)-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol

diphenyl-[(3S)-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol

C22H21NO (315.1623)


   

4-(DIMETHYLAMINO)BENZALDEHYDE DIPHENYLHYDRAZONE

4-(DIMETHYLAMINO)BENZALDEHYDE DIPHENYLHYDRAZONE

C21H21N3 (315.1735)


   

Dihydroethidium

Dihydroethidium

C21H21N3 (315.1735)


   

Boc-(S)-3-Amino-3-(1-naphthyl)-propionic acid

Boc-(S)-3-Amino-3-(1-naphthyl)-propionic acid

C18H21NO4 (315.1471)


   

(R)-N-Boc-1-Naphthylalanine

(R)-N-Boc-1-Naphthylalanine

C18H21NO4 (315.1471)


   

6-[propyl(2-thiophen-3-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol

6-[propyl(2-thiophen-3-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol

C19H25NOS (315.1657)


   

Boc-(R)-3-Amino-3-(1-naphthyl)-propionic acid

Boc-(R)-3-Amino-3-(1-naphthyl)-propionic acid

C18H21NO4 (315.1471)


   

2-(BIPHENYL-3-YL)-N-PHENETHYLACETAMIDE

2-(BIPHENYL-3-YL)-N-PHENETHYLACETAMIDE

C22H21NO (315.1623)


   
   

4-Piperidinecarboxamide,4-(cyclohexylamino)-1-(phenylmethyl)-

4-Piperidinecarboxamide,4-(cyclohexylamino)-1-(phenylmethyl)-

C19H29N3O (315.2311)


   

1-Benzhydryl-3-phenoxy-azetidine

1-Benzhydryl-3-phenoxy-azetidine

C22H21NO (315.1623)


   

Boc-D-Asp(OcHex)-OH

Boc-D-Asp(OcHex)-OH

C15H25NO6 (315.1682)


   

(S)-N-Boc-1-Naphthylalanine

(S)-N-Boc-1-Naphthylalanine

C18H21NO4 (315.1471)


   

Boc-3-(2-naphthyl)-D-alanine

Boc-3-(2-naphthyl)-D-alanine

C18H21NO4 (315.1471)


   

Boc-3-(2-Naphthyl)-L-alanine

Boc-3-(2-Naphthyl)-L-alanine

C18H21NO4 (315.1471)


   

1-(Pyrrolidin-1-yl)-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethanone

1-(Pyrrolidin-1-yl)-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethanone

C18H26BNO3 (315.2006)


   

tert-butyl 3-(quinoxalin-2-yloxy)pyrrolidine-1-carboxylate

tert-butyl 3-(quinoxalin-2-yloxy)pyrrolidine-1-carboxylate

C17H21N3O3 (315.1583)


   

dibutyl hydrogen phosphate, compound with 2,2-iminodiethanol (1:1)

dibutyl hydrogen phosphate, compound with 2,2-iminodiethanol (1:1)

C12H30NO6P (315.1811)


   

Methanone, (3,5-dimethyl-4-isoxazolyl)[4-(3-methoxyphenyl)-1-piperazinyl]-

Methanone, (3,5-dimethyl-4-isoxazolyl)[4-(3-methoxyphenyl)-1-piperazinyl]-

C17H21N3O3 (315.1583)


   

(Z)-2-Methoxy-5-(3,4,5-Trimethoxystyryl)Aniline

(Z)-2-Methoxy-5-(3,4,5-Trimethoxystyryl)Aniline

C18H21NO4 (315.1471)


   

TERT-BUTYL 3-OXO-2-PHENYL-2,3,4,5-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDINE-6(7H)-CARBOXYLATE

TERT-BUTYL 3-OXO-2-PHENYL-2,3,4,5-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDINE-6(7H)-CARBOXYLATE

C17H21N3O3 (315.1583)


   

1-benzhydryl-3-phenylazetidin-3-ol

1-benzhydryl-3-phenylazetidin-3-ol

C22H21NO (315.1623)


   

4-(Piperidine-1-carbonyl)phenylboronic acid pinacol ester

4-(Piperidine-1-carbonyl)phenylboronic acid pinacol ester

C18H26BNO3 (315.2006)


   

TERT-BUTYL 5-(4-METHYLPIPERAZIN-1-YL)-1H-INDOLE-1-CARBOXYLATE

TERT-BUTYL 5-(4-METHYLPIPERAZIN-1-YL)-1H-INDOLE-1-CARBOXYLATE

C18H25N3O2 (315.1947)


   

Moxisylyte hydrochloride

Moxisylyte hydrochloride

C16H26ClNO3 (315.1601)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D008916 - Miotics D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents Moxisylyte (hydrochloride) is (alpha 1-blocker) antagonist, it can vasodilates cerebral vessels without reducing blood pressure. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. [1][2]

   

N-Myristoyl-L-serine

N-Myristoyl-L-serine

C17H33NO4 (315.2409)


   

4-Dibenzylamino-2-methylbenzo-aldehyde

4-Dibenzylamino-2-methylbenzo-aldehyde

C22H21NO (315.1623)


   

Morphinan-6,10-diol,7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5a,6a)-

Morphinan-6,10-diol,7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5a,6a)-

C18H21NO4 (315.1471)


   

(R)-3-Cyclopentyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanenitrile

(R)-3-Cyclopentyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanenitrile

C17H26BN3O2 (315.2118)


   

Ethyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-2-carboxylate

Ethyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-2-carboxylate

C17H22BNO4 (315.1642)


   

(S)-3-((tert-butoxycarbonyl)amino)-3-(naphthalen-2-yl)propanoic acid

(S)-3-((tert-butoxycarbonyl)amino)-3-(naphthalen-2-yl)propanoic acid

C18H21NO4 (315.1471)


   

(R)-Boc-3-(2-naphthyl)-β-Ala-OH

(R)-Boc-3-(2-naphthyl)-β-Ala-OH

C18H21NO4 (315.1471)


   

2-((tert-butoxycarbonyl)amino)-3-(naphthalen-1-yl)propanoic acid

2-((tert-butoxycarbonyl)amino)-3-(naphthalen-1-yl)propanoic acid

C18H21NO4 (315.1471)


   

DIETHYL 1,5-DIMETHYL-3-PHENYL-1H-PYRROLE-2,4-DICARBOXYLATE

DIETHYL 1,5-DIMETHYL-3-PHENYL-1H-PYRROLE-2,4-DICARBOXYLATE

C18H21NO4 (315.1471)


   

3-ACETYL-N-TRIISOPROPYLSILYL INDOLE

3-ACETYL-N-TRIISOPROPYLSILYL INDOLE

C19H29NOSi (315.2018)


   

(4R,4aS,7S,7aR,12bS)-9-methoxy-3-methyl-1,2,4,7,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7-diol

(4R,4aS,7S,7aR,12bS)-9-methoxy-3-methyl-1,2,4,7,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7-diol

C18H21NO4 (315.1471)


   
   

Lauroyliminodiacetic acid

Lauroyliminodiacetic acid

C16H29NO5 (315.2046)


   

(S)-3-(1-Boc-2-piperazinylmethyl)indole

(S)-3-(1-Boc-2-piperazinylmethyl)indole

C18H25N3O2 (315.1947)


   

Boc-12-Ado-OH

Boc-12-Ado-OH

C17H33NO4 (315.2409)


   

(R,R)-OCTAHYDRO-BENZOIMIDAZOLE-2-THIONE

(R,R)-OCTAHYDRO-BENZOIMIDAZOLE-2-THIONE

C18H21NO4 (315.1471)


   

Boc-(R,S)-3-amino-3-(2-naphthyl)-proponic acid

Boc-(R,S)-3-amino-3-(2-naphthyl)-proponic acid

C18H21NO4 (315.1471)


   

6-chloro-N-cyclopentyl-5-(4-ethylphenyl)-2-methylpyrimidin-4-amine

6-chloro-N-cyclopentyl-5-(4-ethylphenyl)-2-methylpyrimidin-4-amine

C18H22ClN3 (315.1502)


   

(2E)-2-(1,3-BENZOTHIAZOL-2-YL)-3-[4-(DIMETHYLAMINO)PHENYL]ACRYLONITRILE

(2E)-2-(1,3-BENZOTHIAZOL-2-YL)-3-[4-(DIMETHYLAMINO)PHENYL]ACRYLONITRILE

C22H21NO (315.1623)


   

R-Mitiglinide Calcium

R-Mitiglinide Calcium

C19H25NO3 (315.1834)


   

(1R,3R,5R)-2-[(2R)-2-Amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile

(1R,3R,5R)-2-[(2R)-2-Amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile

C18H25N3O2 (315.1947)


   

Saxagliptin (S,R,S,S)-Isomer

Saxagliptin (S,R,S,S)-Isomer

C18H25N3O2 (315.1947)


   

Saxagliptin (R,S,R,S)-Isomer

Saxagliptin (R,S,R,S)-Isomer

C18H25N3O2 (315.1947)


   

8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDINYLIDENE)-5H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDINE-D5

8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDINYLIDENE)-5H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDINE-D5

C19H14ClD5N2 (315.1551)


   

2-(3-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)propyl)isoindoline-1,3-dione

2-(3-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)propyl)isoindoline-1,3-dione

C17H22BNO4 (315.1642)


   

5-Amino-1-Boc-3,4,5,6-tetrahydro-2H-[2,4]bipyridinyl hydrochloride

5-Amino-1-Boc-3,4,5,6-tetrahydro-2H-[2,4]bipyridinyl hydrochloride

C15H26ClN3O2 (315.1713)


   
   

Tert-Butyl 5-Methyl-3-Oxo-2,3-Dihydrospiro[Indene-1,4-Piperidine]-1-Carboxylate

Tert-Butyl 5-Methyl-3-Oxo-2,3-Dihydrospiro[Indene-1,4-Piperidine]-1-Carboxylate

C19H25NO3 (315.1834)


   

3-(2-phenyl-2-Cyclopentyl-2-hydroxyethoxy)quinuclidine

3-(2-phenyl-2-Cyclopentyl-2-hydroxyethoxy)quinuclidine

C20H29NO2 (315.2198)


   

1-(1-Ethoxycarbonyl-4-piperidinyl)-4-phenyl-4-imidazolin-2-one

1-(1-Ethoxycarbonyl-4-piperidinyl)-4-phenyl-4-imidazolin-2-one

C17H21N3O3 (315.1583)


   

TERT-BUTYL 4-OXO-3,4-DIHYDRO-2H-SPIRO[NAPHTHALENE-1,4-PIPERIDINE]-1-CARBOXYLATE

TERT-BUTYL 4-OXO-3,4-DIHYDRO-2H-SPIRO[NAPHTHALENE-1,4-PIPERIDINE]-1-CARBOXYLATE

C19H25NO3 (315.1834)


   

benzyl 4-(3-methoxy-3-oxopropyl)-3,5-dimethyl-1H-pyrrole-2-carboxylate

benzyl 4-(3-methoxy-3-oxopropyl)-3,5-dimethyl-1H-pyrrole-2-carboxylate

C18H21NO4 (315.1471)


   

3-(Piperidine-1-carbonyl)phenylboronic acid, pinacol ester

3-(Piperidine-1-carbonyl)phenylboronic acid, pinacol ester

C18H26BNO3 (315.2006)


   

pamaquine

pamaquine

C19H29N3O (315.2311)


C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent

   

N-Acetylglutaminylglutamine amide

N-Acetylglutaminylglutamine amide

C12H21N5O5 (315.1543)


   

4H-Cyclopenta[a][1,3]dioxolo[4,5-h]pyrrolo[2,1-b][3]benzazepin-1-ol, 1,5,6,8,9,14b-hexahydro-2-methoxy-

4H-Cyclopenta[a][1,3]dioxolo[4,5-h]pyrrolo[2,1-b][3]benzazepin-1-ol, 1,5,6,8,9,14b-hexahydro-2-methoxy-

C18H21NO4 (315.1471)


   

2-[[2-[(2-Amino-3-methylbutanoyl)amino]-3-methylbutanoyl]amino]-3-methylbutanoic acid

2-[[2-[(2-Amino-3-methylbutanoyl)amino]-3-methylbutanoyl]amino]-3-methylbutanoic acid

C15H29N3O4 (315.2158)


   

H-Val-Val-Val-OH

H-Val-Val-Val-OH

C15H29N3O4 (315.2158)


   

Leu-Leu-Ala

Leu-Leu-Ala

C15H29N3O4 (315.2158)


A tripeptide composed of two L-leucine units joined to L-alanine by a peptide linkage.

   

Talibegron

Talibegron

C18H21NO4 (315.1471)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist

   

17beta-Hydroxy-androstano[3,2-c]isoxazole

17beta-Hydroxy-androstano[3,2-c]isoxazole

C20H29NO2 (315.2198)


   

(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]propanoyl]amino]-4-methylpentanoic acid

(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]propanoyl]amino]-4-methylpentanoic acid

C15H29N3O4 (315.2158)


   

L-Leucine, L-seryl-L-prolyl-

L-Leucine, L-seryl-L-prolyl-

C14H25N3O5 (315.1794)


   

4,4-[(4-Iminocyclohexa-2,5-dien-1-ylidene)methylene]bis(2-methylaniline)

4,4-[(4-Iminocyclohexa-2,5-dien-1-ylidene)methylene]bis(2-methylaniline)

C21H21N3 (315.1735)


   

L-Alanine, L-isoleucyl-L-isoleucyl-

L-Alanine, L-isoleucyl-L-isoleucyl-

C15H29N3O4 (315.2158)


   

Percodan

Percodan

C18H21NO4 (315.1471)


D000893 - Anti-Inflammatory Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D012459 - Salicylates D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids

   

2-Butoxy-N-[2-(dimethylamino)ethyl]quinoline-4-carboxamide

2-Butoxy-N-[2-(dimethylamino)ethyl]quinoline-4-carboxamide

C18H25N3O2 (315.1947)


   

N-Dodecylphthalimide

N-Dodecylphthalimide

C20H29NO2 (315.2198)


   

(R)-N1-((S)-3,3-Dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide

2-[(Dihydroxycarbonimidoyl)methyl]-N-[2,2-dimethyl-1-(methyl-C-hydroxycarbonimidoyl)propyl]-4-methylpentanimidate

C15H29N3O4 (315.2158)


   

gibberellin A12 aldehyde(1-)

gibberellin A12 aldehyde(1-)

C20H27O3- (315.196)


   

C19-gibberellin skeleton

C19-gibberellin skeleton

C19H23O4- (315.1596)


   

N-(3-oxododecanoyl)-L-homoserine

N-(3-oxododecanoyl)-L-homoserine

C16H29NO5 (315.2046)


   

15-deoxy-Delta(12,14)-prostaglandin J2(1-)

15-deoxy-Delta(12,14)-prostaglandin J2(1-)

C20H27O3- (315.196)


A prostaglandin carboxylic acid anion that is the conjugate base of 15-deoxy-Delta(12,14)-prostaglandin J2. obtained by deprotonation of the carboxy group; major species at pH 7.3. D007155 - Immunologic Factors

   

kauralexin B3

kauralexin B3

C20H27O3- (315.196)


   
   

(+)-Norprotosinomenine

(+)-Norprotosinomenine

C18H21NO4 (315.1471)


   

(1R)-1-[(4-hydroxy-3-methoxyphenyl)methyl]-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol

(1R)-1-[(4-hydroxy-3-methoxyphenyl)methyl]-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol

C18H21NO4 (315.1471)


   

(3aS,6R,7aS)-6-ethyl-N-[(2S)-2-ethyl-1-prop-1-en-2-ylcyclopropyl]-1-oxo-2,3,3a,6,7,7a-hexahydroindene-4-carboxamide

(3aS,6R,7aS)-6-ethyl-N-[(2S)-2-ethyl-1-prop-1-en-2-ylcyclopropyl]-1-oxo-2,3,3a,6,7,7a-hexahydroindene-4-carboxamide

C20H29NO2 (315.2198)


   

7-Oxononanoylcarnitine

7-Oxononanoylcarnitine

C16H29NO5 (315.2046)


   

5-Oxononanoylcarnitine

5-Oxononanoylcarnitine

C16H29NO5 (315.2046)


   

8-Oxononanoylcarnitine

8-Oxononanoylcarnitine

C16H29NO5 (315.2046)


   

3-Oxononanoylcarnitine

3-Oxononanoylcarnitine

C16H29NO5 (315.2046)


   

6-Oxononanoylcarnitine

6-Oxononanoylcarnitine

C16H29NO5 (315.2046)


   

4-Oxononanoylcarnitine

4-Oxononanoylcarnitine

C16H29NO5 (315.2046)


   

9-Oxononanoylcarnitine

9-Oxononanoylcarnitine

C16H29NO5 (315.2046)


   

6-Methylnonanoylcarnitine

6-Methylnonanoylcarnitine

C17H33NO4 (315.2409)


   

5-Methylnonanoylcarnitine

5-Methylnonanoylcarnitine

C17H33NO4 (315.2409)


   

8-Methylnonanoylcarnitine

8-Methylnonanoylcarnitine

C17H33NO4 (315.2409)


   

7-Methylnonanoylcarnitine

7-Methylnonanoylcarnitine

C17H33NO4 (315.2409)


   

4-Methylnonanoylcarnitine

4-Methylnonanoylcarnitine

C17H33NO4 (315.2409)


   

3-Methylnonanoylcarnitine

3-Methylnonanoylcarnitine

C17H33NO4 (315.2409)


   

6-Hydroxynon-7-enoylcarnitine

6-Hydroxynon-7-enoylcarnitine

C16H29NO5 (315.2046)


   

Oct-4-enedioylcarnitine

Oct-4-enedioylcarnitine

C15H25NO6 (315.1682)


   

Oct-5-enedioylcarnitine

Oct-5-enedioylcarnitine

C15H25NO6 (315.1682)


   

6-Hydroxynon-3-enoylcarnitine

6-Hydroxynon-3-enoylcarnitine

C16H29NO5 (315.2046)


   

6-Hydroxynon-4-enoylcarnitine

6-Hydroxynon-4-enoylcarnitine

C16H29NO5 (315.2046)


   

6-Hydroxynon-5-enoylcarnitine

6-Hydroxynon-5-enoylcarnitine

C16H29NO5 (315.2046)


   

6-Hydroxynon-6-enoylcarnitine

6-Hydroxynon-6-enoylcarnitine

C16H29NO5 (315.2046)


   

(6Z)-Oct-6-enedioylcarnitine

(6Z)-Oct-6-enedioylcarnitine

C15H25NO6 (315.1682)


   

(2E)-Oct-2-enedioylcarnitine

(2E)-Oct-2-enedioylcarnitine

C15H25NO6 (315.1682)


   

(2Z)-6-Hydroxynon-2-enoylcarnitine

(2Z)-6-Hydroxynon-2-enoylcarnitine

C16H29NO5 (315.2046)


   

(4aR,4bR,7R,9aR,10S,10aR)-1-methyl-8-methylene-13-oxododecahydro-4a,1-(epoxymethano)-7,9a-methanobenzo[a]azulene-10-carboxylate

(4aR,4bR,7R,9aR,10S,10aR)-1-methyl-8-methylene-13-oxododecahydro-4a,1-(epoxymethano)-7,9a-methanobenzo[a]azulene-10-carboxylate

C19H23O4- (315.1596)


   

Aculene A

Aculene A

C19H25NO3 (315.1834)


A carboxylic ester resulting from the formal condensation of the hydroxy group of aculene C with the carboxylic acid group of L-proline. It is a sesquiterpenoid isolated from the fungus Aspergillus aculeatus.

   
   

N9-(4-butoxyphenyl)-6,8,10-triazaspiro[4.5]deca-6,9-diene-7,9-diamine

N9-(4-butoxyphenyl)-6,8,10-triazaspiro[4.5]deca-6,9-diene-7,9-diamine

C17H25N5O (315.2059)


   

N-(2-ethoxyphenyl)-2-(4-methoxyphenoxy)propanamide

N-(2-ethoxyphenyl)-2-(4-methoxyphenoxy)propanamide

C18H21NO4 (315.1471)


   

2-oxo-1,4-dihydroquinazoline-3-carboxylic acid [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] ester

2-oxo-1,4-dihydroquinazoline-3-carboxylic acid [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] ester

C17H21N3O3 (315.1583)


   

N-(3,7-dimethyl-2,6-octadienylidene)-2-nitrobenzohydrazide

N-(3,7-dimethyl-2,6-octadienylidene)-2-nitrobenzohydrazide

C17H21N3O3 (315.1583)


   

(12S)-4,5-Dimethoxy-12-methyl-13-oxa-10-azatetracyclo[8.7.0.02,7.011,15]heptadeca-2,4,6,11(15)-tetraen-14-one

(12S)-4,5-Dimethoxy-12-methyl-13-oxa-10-azatetracyclo[8.7.0.02,7.011,15]heptadeca-2,4,6,11(15)-tetraen-14-one

C18H21NO4 (315.1471)


   
   

Pyranonigrin E

Pyranonigrin E

C18H21NO4 (315.1471)


A member of the class of pyranopyrroles with formula C18H21NO4, originally isolated from Aspergillus niger.

   

N-benzyl-2,2-diphenylpropanamide

N-benzyl-2,2-diphenylpropanamide

C22H21NO (315.1623)


   
   

6-Amino-2-methyl-8-phenyl-1,6,8,8a-tetrahydroisoquinoline-5,7,7-tricarbonitrile

6-Amino-2-methyl-8-phenyl-1,6,8,8a-tetrahydroisoquinoline-5,7,7-tricarbonitrile

C19H17N5 (315.1484)


   

4-Methyl-6-[2-(4-methyl-1-piperidinyl)-2-oxoethoxy]-1-benzopyran-2-one

4-Methyl-6-[2-(4-methyl-1-piperidinyl)-2-oxoethoxy]-1-benzopyran-2-one

C18H21NO4 (315.1471)


   

1,3-Dimethyl-5-[1-(1-phenylethylamino)propylidene]-1,3-diazinane-2,4,6-trione

1,3-Dimethyl-5-[1-(1-phenylethylamino)propylidene]-1,3-diazinane-2,4,6-trione

C17H21N3O3 (315.1583)


   

N-(4-fluorophenyl)-6-methyl-1-propyl-3,4-dihydro-1H-pyrrolo[1,2-a]pyrazine-2-carboxamide

N-(4-fluorophenyl)-6-methyl-1-propyl-3,4-dihydro-1H-pyrrolo[1,2-a]pyrazine-2-carboxamide

C18H22FN3O (315.1747)


   

all-trans-(4S)-hydroxyretinoate

all-trans-(4S)-hydroxyretinoate

C20H27O3- (315.196)


   

all-trans-4-Hydroxyretinoate

all-trans-4-Hydroxyretinoate

C20H27O3- (315.196)


A hydroxy monocarboxylic acid anion that is the conjugate base of all-trans-4-hydroxyretinoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

N-(3,7-dimethyl-2,6-octadien-1-ylidene)-4-nitrobenzohydrazide

N-(3,7-dimethyl-2,6-octadien-1-ylidene)-4-nitrobenzohydrazide

C17H21N3O3 (315.1583)


   

N-cycloheptyl-3-(5,7-dioxo-6-pyrrolo[3,4-b]pyridinyl)propanamide

N-cycloheptyl-3-(5,7-dioxo-6-pyrrolo[3,4-b]pyridinyl)propanamide

C17H21N3O3 (315.1583)


   

all-trans-18-Hydroxyretinoate

all-trans-18-Hydroxyretinoate

C20H27O3- (315.196)


A retinoid anion that is the conjugate base of all-trans-18-hydroxyretinoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(1R,5S)-6-[[5-(2-fluoro-4-methoxyphenyl)-1H-pyrazol-4-yl]methyl]-6-azabicyclo[3.2.1]octane

(1R,5S)-6-[[5-(2-fluoro-4-methoxyphenyl)-1H-pyrazol-4-yl]methyl]-6-azabicyclo[3.2.1]octane

C18H22FN3O (315.1747)


   
   

(2E,4E,6E,8E)-3,7-dimethyl-9-(2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)nona-2,4,6,8-tetraenoate

(2E,4E,6E,8E)-3,7-dimethyl-9-(2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)nona-2,4,6,8-tetraenoate

C20H27O3- (315.196)


   

(5-Methyl-1,2-oxazol-3-yl)-[4-(5-propylpyrimidin-2-yl)piperazin-1-yl]methanone

(5-Methyl-1,2-oxazol-3-yl)-[4-(5-propylpyrimidin-2-yl)piperazin-1-yl]methanone

C16H21N5O2 (315.1695)


   

[(E)-1-[5-(3-methylbutoxymethyl)-2-oxooxolan-3-yl]propan-2-ylideneamino]thiourea

[(E)-1-[5-(3-methylbutoxymethyl)-2-oxooxolan-3-yl]propan-2-ylideneamino]thiourea

C14H25N3O3S (315.1617)


   

3-O-Acetyl-8-O-demethylmaritidine

3-O-Acetyl-8-O-demethylmaritidine

C18H21NO4 (315.1471)


   
   
   
   
   
   
   
   
   
   
   
   

Alanine, N-methyl-N-methoxycarbonyl-, undecyl ester

Alanine, N-methyl-N-methoxycarbonyl-, undecyl ester

C17H33NO4 (315.2409)


   

(1-Methyl-3-imidazo[1,2-a]pyridin-4-iumyl)-diphenylmethanol

(1-Methyl-3-imidazo[1,2-a]pyridin-4-iumyl)-diphenylmethanol

C21H19N2O+ (315.1497)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

(2E)-7-carboxyhept-2-enoylcarnitine

(2E)-7-carboxyhept-2-enoylcarnitine

C15H25NO6 (315.1682)


An O-acylcarnitine having (2E)-7-carboxyhept-2-enoyl as the acyl substituent.

   
   

Ectocarpin B

Ectocarpin B

C20H27O3- (315.196)


   
   

All-trans-16-hydroxyretinoate

All-trans-16-hydroxyretinoate

C20H27O3- (315.196)


   

5-Oxoeicosapentaenoate

5-Oxoeicosapentaenoate

C20H27O3- (315.196)


   

Huprine 19 dication

Huprine 19 dication

C18H22ClN3+2 (315.1502)


   

9-cis-4-Hydroxyretinoate

9-cis-4-Hydroxyretinoate

C20H27O3- (315.196)


   

(2E)-10-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]dec-2-enoate

(2E)-10-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]dec-2-enoate

C16H27O6- (315.1808)


   

(3R)-3-decanoyloxy-4-[dimethyl(trideuteriomethyl)azaniumyl]butanoate

(3R)-3-decanoyloxy-4-[dimethyl(trideuteriomethyl)azaniumyl]butanoate

C17H33NO4 (315.2409)


   

(E,9R)-9-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxydec-2-enoate

(E,9R)-9-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxydec-2-enoate

C16H27O6- (315.1808)


   

4-Oxo-all-trans-13,14-dihydroretinoate

4-Oxo-all-trans-13,14-dihydroretinoate

C20H27O3- (315.196)


   

(1S)-1-(3-Hydroxy-4-methoxybenzyl)-2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline

(1S)-1-(3-Hydroxy-4-methoxybenzyl)-2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline

C18H21NO4 (315.1471)


   

Saxagliptin (BMS-477118,Onglyza)

Saxagliptin (BMS-477118,Onglyza)

C18H25N3O2 (315.1947)


A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D054795 - Incretins D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors

   

2-Ethoxy-N-(2-(diethylamino)ethyl)-4-quinolinecarboxamide

2-Ethoxy-N-(2-(diethylamino)ethyl)-4-quinolinecarboxamide

C18H25N3O2 (315.1947)


   

2-Butoxy-N-(2-(ethylamino)ethyl)-4-quinolinecarboxamide

2-Butoxy-N-(2-(ethylamino)ethyl)-4-quinolinecarboxamide

C18H25N3O2 (315.1947)


   

N-methylcoclaurine N-oxide

N-methylcoclaurine N-oxide

C18H21NO4 (315.1471)


   

N-Acetyl-alanyl-valyl-alanine methyl ester

N-Acetyl-alanyl-valyl-alanine methyl ester

C14H25N3O5 (315.1794)


   

N-Acetyl-alanyl-leucyl-glycine methylester

N-Acetyl-alanyl-leucyl-glycine methylester

C14H25N3O5 (315.1794)


   

N-Acetyl-glycyl-leucyl-alanine methylester

N-Acetyl-glycyl-leucyl-alanine methylester

C14H25N3O5 (315.1794)


   

2-Ethoxycarbonyl-3-ethyl-4-methyl-5-benzyloxycarbonyl-pyrrole

2-Ethoxycarbonyl-3-ethyl-4-methyl-5-benzyloxycarbonyl-pyrrole

C18H21NO4 (315.1471)


   

2,4-Diisopropyl-4,4A-dihydro-1H-(1,3,5)triazino(1,2-A)quinoline-1,3,6(2H,5H)-trione

2,4-Diisopropyl-4,4A-dihydro-1H-(1,3,5)triazino(1,2-A)quinoline-1,3,6(2H,5H)-trione

C17H21N3O3 (315.1583)


   

O-Decanoyl-L-carnitine

O-Decanoyl-L-carnitine

C17H33NO4 (315.2409)


An O-acyl-L-carnitine that is L-carnitine having decanoyl as the acyl substituent.

   

(R)-Norreticuline

(R)-Norreticuline

C18H21NO4 (315.1471)


   

(+)-pisiferate

(+)-pisiferate

C20H27O3 (315.196)


A monocarboxylic acid anion that is the conjugate base of (+)-pisiferic acid, arising from the deprotonation of the carboxy group. Major species at pH 7.3.

   

(±)-Rotigotine

1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-

C19H25NOS (315.1657)


D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists

   
   

O-decanoylcarnitine

O-decanoylcarnitine

C17H33NO4 (315.2409)


An O-acylcarnitine compound having decanoyl as the acyl substituent.

   

3,7-Diamino-2,8-dimethyl-5-phenylphenazin-5-ium

3,7-Diamino-2,8-dimethyl-5-phenylphenazin-5-ium

C20H19N4+ (315.161)


   

(S)-all-trans-4-hydroxyretinoate

(S)-all-trans-4-hydroxyretinoate

C20H27O3 (315.196)


An all-trans-4-hydroxyretinoate that is the conjugate base of (S)-all-trans-4-hydroxyretinoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

oscr#15(1-)

oscr#15(1-)

C16H27O6 (315.1808)


A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#15, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

ascr#15(1-)

ascr#15(1-)

C16H27O6 (315.1808)


Conjugate base of ascr#15

   

O-octenedioylcarnitine

O-octenedioylcarnitine

C15H25NO6 (315.1682)


An O-acylcarnitine obtained by formal condensation of one of the carboxy groups of any octenedioic acid with the hydroxy group of carnitine.

   

gibberellin A9(1-)

gibberellin A9(1-)

C19H23O4 (315.1596)


A gibberellin carboxylic acid anion that is the conjugate base of gibberellin A9, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

5,6-epoxyretinoate

5,6-epoxyretinoate

C20H27O3 (315.196)


A monocarboxylic acid anion that is the conjugate base of 5,6-epoxyretinoic acid arising from deprotonation of the carboxylic acid function; major species at pH 7.3.

   

(R,S)-Norreticuline

(R,S)-Norreticuline

C18H21NO4 (315.1471)


   
   
   
   
   
   
   
   
   
   
   
   
   

A-804598

A-804598

C19H17N5 (315.1484)


A-804598 is a CNS penetrant, competitive and selective P2X7 receptor antagonist with IC50s of 9 nM, 10 nM and 11 nM for mouse, rat and human P2X7 receptors, respectively[1].

   

NG-497

NG-497

C18H21NO4 (315.1471)


NG-497 is a selective human adipose triglyceride lipase (ATGL) inhibitor that targets the enzymatically active patatin-like domain of human ATGL. NG-497 has potential value for tumor research[1].

   

7,8-dimethoxy-2h,4h,5h,10h,11h-indolo[7a,1-a]isoquinoline-5,11-diol

7,8-dimethoxy-2h,4h,5h,10h,11h-indolo[7a,1-a]isoquinoline-5,11-diol

C18H21NO4 (315.1471)


   

(1s,15r,16s)-5-hydroxy-4-methoxy-9-azatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-2(7),3,5,12-tetraen-15-yl acetate

(1s,15r,16s)-5-hydroxy-4-methoxy-9-azatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-2(7),3,5,12-tetraen-15-yl acetate

C18H21NO4 (315.1471)


   

1-{14-hydroxy-9-methoxy-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6,8,10(17),15-tetraen-4-yl}ethanone

1-{14-hydroxy-9-methoxy-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6,8,10(17),15-tetraen-4-yl}ethanone

C18H21NO4 (315.1471)


   

(2s,3s,10r,12s)-12-methoxy-4-methyl-11,16,18-trioxa-4-azapentacyclo[11.7.0.0²,¹⁰.0³,⁷.0¹⁵,¹⁹]icosa-1(20),7,13,15(19)-tetraene

(2s,3s,10r,12s)-12-methoxy-4-methyl-11,16,18-trioxa-4-azapentacyclo[11.7.0.0²,¹⁰.0³,⁷.0¹⁵,¹⁹]icosa-1(20),7,13,15(19)-tetraene

C18H21NO4 (315.1471)


   

3,17,17-trimethyl-7-methylidene-15-azatricyclo[8.5.2.0¹³,¹⁶]heptadeca-3,13(16),14-triene-5,14-diol

3,17,17-trimethyl-7-methylidene-15-azatricyclo[8.5.2.0¹³,¹⁶]heptadeca-3,13(16),14-triene-5,14-diol

C20H29NO2 (315.2198)


   

1-[3-(2-hydroxy-3-methoxy-3-methylbutyl)-1h-indol-5-yl]-3-methylbut-2-en-1-one

1-[3-(2-hydroxy-3-methoxy-3-methylbutyl)-1h-indol-5-yl]-3-methylbut-2-en-1-one

C19H25NO3 (315.1834)


   

(1s,14r,17r)-5,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,15-tetraen-4-ol

(1s,14r,17r)-5,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,15-tetraen-4-ol

C19H25NO3 (315.1834)


   

(10s,13s)-10-[(2s)-butan-2-yl]-13-(hydroxymethyl)-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

(10s,13s)-10-[(2s)-butan-2-yl]-13-(hydroxymethyl)-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

C18H25N3O2 (315.1947)


   

(1r,7ar)-1-hydroxy-7-({[(2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

(1r,7ar)-1-hydroxy-7-({[(2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

C15H25NO6 (315.1682)


   

octahydro-1h-quinolizin-1-ylmethyl 3-(4-hydroxyphenyl)prop-2-enoate

octahydro-1h-quinolizin-1-ylmethyl 3-(4-hydroxyphenyl)prop-2-enoate

C19H25NO3 (315.1834)


   

7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hept-2-en-1-one

7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hept-2-en-1-one

C19H25NO3 (315.1834)


   

amuroline

NA

C19H25NO3 (315.1834)


{"Ingredient_id": "HBIN015930","Ingredient_name": "amuroline","Alias": "NA","Ingredient_formula": "C19H25NO3","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1100","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

(1s,17r)-4,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-5-ol

(1s,17r)-4,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-5-ol

C19H25NO3 (315.1834)


   

5-[3-(4-hydroxy-4-methylpent-2-en-1-yl)-3-methyloxiran-2-yl]-3-methyl-1-(1h-pyrrol-2-yl)penta-2,4-dien-1-one

5-[3-(4-hydroxy-4-methylpent-2-en-1-yl)-3-methyloxiran-2-yl]-3-methyl-1-(1h-pyrrol-2-yl)penta-2,4-dien-1-one

C19H25NO3 (315.1834)


   

5,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-4-ol

5,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-4-ol

C19H25NO3 (315.1834)


   

(1s,7ar)-1-hydroxy-7-({[(2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

(1s,7ar)-1-hydroxy-7-({[(2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

C15H25NO6 (315.1682)


   

13-(hydroxymethyl)-9-methyl-10-(sec-butyl)-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

13-(hydroxymethyl)-9-methyl-10-(sec-butyl)-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

C18H25N3O2 (315.1947)


   

(1r,2s,4'r)-10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),3,8'(12'),9'-tetraen-2-ol

(1r,2s,4'r)-10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),3,8'(12'),9'-tetraen-2-ol

C19H25NO3 (315.1834)


   

5-(3,7-dimethylocta-2,6-dien-1-yl)-6-methoxy-3h-isoindole-1,4-diol

5-(3,7-dimethylocta-2,6-dien-1-yl)-6-methoxy-3h-isoindole-1,4-diol

C19H25NO3 (315.1834)


   

10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-ol

10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-ol

C19H25NO3 (315.1834)


   

5-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6-methoxy-3h-isoindole-1,4-diol

5-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6-methoxy-3h-isoindole-1,4-diol

C19H25NO3 (315.1834)


   

(3ar,4s)-1-ethyl-3a,6-dimethyl-3-oxo-4,5-dihydroazulen-4-yl (2s)-pyrrolidine-2-carboxylate

(3ar,4s)-1-ethyl-3a,6-dimethyl-3-oxo-4,5-dihydroazulen-4-yl (2s)-pyrrolidine-2-carboxylate

C19H25NO3 (315.1834)


   

(1s,4r,4's)-10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-ol

(1s,4r,4's)-10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-ol

C19H25NO3 (315.1834)


   

5-hydroxy-3-{4-[(3-methylbut-3-en-1-yl)oxy]phenyl}-4-(2-methylpropyl)-3,4-dihydropyrrol-2-one

5-hydroxy-3-{4-[(3-methylbut-3-en-1-yl)oxy]phenyl}-4-(2-methylpropyl)-3,4-dihydropyrrol-2-one

C19H25NO3 (315.1834)


   

(1r,7as)-1-({[2-hydroxy-2-(1-hydroxyethyl)-3-methylpentanoyl]oxy}methyl)-hexahydro-1h-pyrrolizin-4-ium-4-olate

(1r,7as)-1-({[2-hydroxy-2-(1-hydroxyethyl)-3-methylpentanoyl]oxy}methyl)-hexahydro-1h-pyrrolizin-4-ium-4-olate

C16H29NO5 (315.2046)


   

4,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-5-ol

4,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-5-ol

C19H25NO3 (315.1834)


   

(1s,9ar)-octahydro-1h-quinolizin-1-ylmethyl (2z)-3-(4-hydroxyphenyl)prop-2-enoate

(1s,9ar)-octahydro-1h-quinolizin-1-ylmethyl (2z)-3-(4-hydroxyphenyl)prop-2-enoate

C19H25NO3 (315.1834)


   

(1r)-1-(3-carbamimidamidopropyl)-2h,3h,4h,9h-pyrido[3,4-b]indole-1-carboxylic acid

(1r)-1-(3-carbamimidamidopropyl)-2h,3h,4h,9h-pyrido[3,4-b]indole-1-carboxylic acid

C16H21N5O2 (315.1695)


   

1-{3-[(2r)-2-hydroxy-3-methoxy-3-methylbutyl]-1h-indol-5-yl}-3-methylbut-2-en-1-one

1-{3-[(2r)-2-hydroxy-3-methoxy-3-methylbutyl]-1h-indol-5-yl}-3-methylbut-2-en-1-one

C19H25NO3 (315.1834)


   

(1r,9ar)-octahydro-1h-quinolizin-1-ylmethyl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

(1r,9ar)-octahydro-1h-quinolizin-1-ylmethyl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

C19H25NO3 (315.1834)


   

3-hydroxy-4-methoxy-9-methyl-9-azapentacyclo[8.8.0.0¹,⁶.0²,¹³.0¹³,¹⁸]octadeca-5,14-dien-16-one

3-hydroxy-4-methoxy-9-methyl-9-azapentacyclo[8.8.0.0¹,⁶.0²,¹³.0¹³,¹⁸]octadeca-5,14-dien-16-one

C19H25NO3 (315.1834)


   

(1s,14r,17r)-4,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,15-tetraen-5-ol

(1s,14r,17r)-4,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,15-tetraen-5-ol

C19H25NO3 (315.1834)


   

1-ethyl-3a,6-dimethyl-3-oxo-4,5-dihydroazulen-4-yl pyrrolidine-2-carboxylate

1-ethyl-3a,6-dimethyl-3-oxo-4,5-dihydroazulen-4-yl pyrrolidine-2-carboxylate

C19H25NO3 (315.1834)


   

(1s,9as)-octahydro-1h-quinolizin-1-ylmethyl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

(1s,9as)-octahydro-1h-quinolizin-1-ylmethyl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

C19H25NO3 (315.1834)


   

4,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,15-tetraen-5-ol

4,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,15-tetraen-5-ol

C19H25NO3 (315.1834)


   

7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hept-6-en-1-one

7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hept-6-en-1-one

C19H25NO3 (315.1834)


   

5,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,15-tetraen-4-ol

5,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,15-tetraen-4-ol

C19H25NO3 (315.1834)


   

(1r,7ar)-1-hydroxy-7-({[(2s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

(1r,7ar)-1-hydroxy-7-({[(2s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

C15H25NO6 (315.1682)


   

10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),3,8'(12'),9'-tetraen-2-ol

10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),3,8'(12'),9'-tetraen-2-ol

C19H25NO3 (315.1834)


   

(1s)-1-(3-carbamimidamidopropyl)-2h,3h,4h,9h-pyrido[3,4-b]indole-1-carboxylic acid

(1s)-1-(3-carbamimidamidopropyl)-2h,3h,4h,9h-pyrido[3,4-b]indole-1-carboxylic acid

C16H21N5O2 (315.1695)


   

(2e,4e)-n-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienimidic acid

(2e,4e)-n-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienimidic acid

C20H29NO2 (315.2198)


   

[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2r)-2,3-dihydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoate

[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2r)-2,3-dihydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoate

C15H25NO6 (315.1682)


   

(1r,3e,5s,10r)-3,17,17-trimethyl-7-methylidene-15-azatricyclo[8.5.2.0¹³,¹⁶]heptadeca-3,13(16),14-triene-5,14-diol

(1r,3e,5s,10r)-3,17,17-trimethyl-7-methylidene-15-azatricyclo[8.5.2.0¹³,¹⁶]heptadeca-3,13(16),14-triene-5,14-diol

C20H29NO2 (315.2198)


   

n-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienimidic acid

n-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienimidic acid

C20H29NO2 (315.2198)


   

(1s,4s,4'r)-10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-ol

(1s,4s,4'r)-10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-ol

C19H25NO3 (315.1834)


   

(1s,17s)-5,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-4-ol

(1s,17s)-5,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-4-ol

C19H25NO3 (315.1834)


   

(2e)-7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hept-2-en-1-one

(2e)-7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hept-2-en-1-one

C19H25NO3 (315.1834)


   

(1s,9ar)-octahydro-1h-quinolizin-1-ylmethyl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

(1s,9ar)-octahydro-1h-quinolizin-1-ylmethyl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

C19H25NO3 (315.1834)


   

(1s,7ar)-1-hydroxy-7-({[(2s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

(1s,7ar)-1-hydroxy-7-({[(2s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

C15H25NO6 (315.1682)


   

(2z,4e)-5-{3-[(2e)-4-hydroxy-4-methylpent-2-en-1-yl]-3-methyloxiran-2-yl}-3-methyl-1-(1h-pyrrol-2-yl)penta-2,4-dien-1-one

(2z,4e)-5-{3-[(2e)-4-hydroxy-4-methylpent-2-en-1-yl]-3-methyloxiran-2-yl}-3-methyl-1-(1h-pyrrol-2-yl)penta-2,4-dien-1-one

C19H25NO3 (315.1834)


   

(1s,5r,13r,14r,17r)-10,14-dimethoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7,9,11(18)-triene

(1s,5r,13r,14r,17r)-10,14-dimethoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7,9,11(18)-triene

C19H25NO3 (315.1834)


   

(1r,7ar)-1-hydroxy-7-({[(2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

(1r,7ar)-1-hydroxy-7-({[(2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

C15H25NO6 (315.1682)


   

(1r,4s,7ar)-1-hydroxy-7-({[(2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

(1r,4s,7ar)-1-hydroxy-7-({[(2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

C15H25NO6 (315.1682)


   

(1r,7as)-1-hydroxy-7-({[(2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

(1r,7as)-1-hydroxy-7-({[(2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

C15H25NO6 (315.1682)


   

(3s,4r)-5-hydroxy-3-{4-[(3-methylbut-3-en-1-yl)oxy]phenyl}-4-(2-methylpropyl)-3,4-dihydropyrrol-2-one

(3s,4r)-5-hydroxy-3-{4-[(3-methylbut-3-en-1-yl)oxy]phenyl}-4-(2-methylpropyl)-3,4-dihydropyrrol-2-one

C19H25NO3 (315.1834)